Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β₂agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial

Abstract

FF/VI (100/25 µg or 200/25 µg) administered once daily over 52 weeks was well tolerated by patients aged ≥12 years with asthma. The overall safety profile of FF/VI did not reveal any findings of significant clinical concern. CLINICALTRIALS.GOV: NCT01018186.